KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Assets Average (2016 - 2025)

Arbutus Biopharma's Assets Average history spans 13 years, with the latest figure at $100.5 million for Q3 2025.

  • For Q3 2025, Assets Average fell 33.12% year-over-year to $100.5 million; the TTM value through Sep 2025 reached $100.5 million, down 33.12%, while the annual FY2024 figure was $138.1 million, 18.75% down from the prior year.
  • Assets Average for Q3 2025 was $100.5 million at Arbutus Biopharma, down from $110.1 million in the prior quarter.
  • Across five years, Assets Average topped out at $209.8 million in Q3 2022 and bottomed at $100.5 million in Q3 2025.
  • The 5-year median for Assets Average is $150.2 million (2024), against an average of $154.2 million.
  • The largest annual shift saw Assets Average skyrocketed 40.64% in 2021 before it plummeted 33.12% in 2025.
  • A 5-year view of Assets Average shows it stood at $140.8 million in 2021, then soared by 41.76% to $199.6 million in 2022, then fell by 24.09% to $151.5 million in 2023, then decreased by 10.19% to $136.1 million in 2024, then fell by 26.15% to $100.5 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Assets Average are $100.5 million (Q3 2025), $110.1 million (Q2 2025), and $124.4 million (Q1 2025).